行情

ALIM

ALIM

Alimera医疗科学
NASDAQ

实时行情|Nasdaq Last Sale

5.26
-0.04
-0.75%
已收盘, 16:00 05/28 EDT
开盘
5.42
昨收
5.30
最高
5.42
最低
5.26
成交量
2,742
成交额
--
52周最高
15.45
52周最低
0.0045
市值
2,646.70万
市盈率(TTM)
-2.8178
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ALIM价格均价为14.75,最高价位18.00,最低价为12.00。

EPS

ALIM 新闻

更多
Edited Transcript of ALIM earnings conference call or presentation 30-Apr-20 1:00pm GMT
Q1 2020 Alimera Sciences Inc Earnings Call
Thomson Reuters StreetEvents · 05/11 11:25
Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/03 11:38
Alimera Sciences Inc (ALIM) Q1 2020 Earnings Call Transcript
Motley Fool · 05/01 01:30
Alimera Sciences EPS beats by $0.32, beats on revenue
Alimera Sciences (NASDAQ:ALIM): Q1 GAAP EPS of -$0.24 beats by $0.32. Revenue of $14.54M (+12.8% Y/Y) beats by $0.78M. Press Release
seekingalpha · 04/30 01:27
Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 44.19% and 3.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 04/29 22:25
Alimera Sciences Q1 Sales $14.535M Beat $13.760M Estimate
Alimera Sciences (NASDAQ:ALIM) reported quarterly sales of $14.535 million which beat the analyst consensus estimate of $13.760 million by 5.63 percent. This is a 12.76 percent increase over sales of $12.890 million the
Benzinga · 04/29 20:02
Alimera Sciences Announces First Quarter 2020 Financial Results and Provides Corporate Update
First Quarter and Recent Company Highlights: Consolidated Net Revenue Up 12% Compared to First Quarter 2019International Net Revenue Up 23% Compared to First Quarter 2019Net.
GlobeNewswire · 04/29 20:00
The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 28.)
Benzinga · 04/29 12:40

所属板块

制药
+1.28%
制药与医学研究
+1.04%

热门股票

代码
价格
涨跌幅

ALIM 简况

Alimera Sciences, Inc.(Alimera)是一家制药公司。该公司从事眼科药品研发及销售业务。该公司经营两个部门:美国部门和国际部门。该公司专注于影响眼球背面或视网膜的疾病。该公司的产品ILUVIEN用于治疗糖尿病性黄斑水肿(DME)。DME是一种影响糖尿病患者视网膜的疾病,可导致严重视力丧失和失明。在美国、加拿大、黎巴嫩和阿联酋,ILUVIEN用于已用皮质类固醇治疗但眼内压(IOP)未升高的患者的DME治疗。在欧洲经济区(EEA)国家,ILUVIEN用于治疗对现有疗法效果不足的DME相关视力障碍。
展开

微牛提供Alimera Sciences Inc(NASDAQ-ALIM)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ALIM股票新闻,以帮助您做出投资决策。